Dermatol. praxi. 2022;16(2):74-78 | DOI: 10.36290/der.2022.014

Impact of biologic treatment on the quality of life in patients with atopic dermatitis

MUDr. Martina Matzenauer, MUDr. Jana Chlebková
Kožní oddělení se stacionářem, Nemocnice Agel Nový Jičín, a. s.

Atopic dermatitis is a chronic inflammatory skin disease with a gradually increasing incidence and prevalence in the population. Depending on the severity of the skin manifestations, it is accompanied by varying degrees of mental disorders and their understanding is essential for a comprehensive approach to the treatment of patients, including psychodermatological care. Equally important is the somatization of mental health problems, which we encounter more and more often in our practice and it is necessary to take them into account. Thanks to new treatment modalities, we are now able not only to relieve patients of their skin symptoms, or to completely suppress them, but also to greatly contribute to mitigating their impact on daily activities and mental health, which ultimately leads to an overall improvement in the quality of life of patients with atopic dermatitis. We have a number of simple tools available to objectify the local findings and the overall impact on patients' quality of life, mainly in the form of questionnaires or on-line calculators, the adoption of which leads to more accurate diagnostics and gives us and our patients valuable feedback with regard to treatment effectiveness.

Keywords: atopic dermatitis, quality of life, mental burden, biologic treatment.

Published: June 7, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matzenauer M, Chlebková J. Impact of biologic treatment on the quality of life in patients with atopic dermatitis. Dermatol. praxi. 2022;16(2):74-78. doi: 10.36290/der.2022.014.
Download citation

References

  1. Meštrović-Štefekov, Jelena & Bilić, Gaby & Kuna, M. & Pap, et al. Psychological Stress in Patients with Atopic Dermatitis. Acta dermatovenerologica Croatica: ADC. 26. 297-303. Go to PubMed...
  2. Pánková R. Atopická dermatitida - co je nového? Dermatol. praxi. 2015;9(1):25-30.
  3. https://www.atopie-online-mezioborove.cz/z-oboru/e-learningovy-kurz-biologicka-lecba-atopicke-dermatitidy-u-deti-a-mladistvych.
  4. Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31(6):606-614. Go to original source... Go to PubMed...
  5. Murota H, Takahashi A, Nishioka M, et al. Showering reduces atopic dermatitis in elementary school students. Eur J Dermatol. 2010;20:410-411. Go to original source... Go to PubMed...
  6. Sutton EL. Psychiatric disorders and sleep issues. Med Clin North Am. 2014;98:1123-1143.  Go to original source... Go to PubMed...
  7. Chrostowska-Plak D, Reich A, Szepietowski JC. Relation­ship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27:e239-e242. Go to original source... Go to PubMed...
  8. Yosipovitch G, Eckert L, Chen Z, et al. Correlations of itch with quality of life and signs.
  9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi: 10.1111/j.1365-2230.1994.tb01167.x. PMID: 8033378. Go to original source... Go to PubMed...
  10. Jorge MFS, Sousa TD, Pollo CF, et al. Dimensionality and psychometric analysis of DLQI in a Brazilian population. Health Qual Life Outcomes 18, 268 (2020). Go to original source... Go to PubMed...
  11. https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/dermatology-life-quality-index.
  12. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-279.e3. doi: 10.1016/j.jaad.2017.04.019. Epub 2017 Jun 9. PMID: 28606711. Go to original source... Go to PubMed...
  13. Podder I, Mondal H, Kroumpouzos G. Nocturnal pruritus and sleep disturbance associated with dermatologic disorders in adult patients. Int J Womens Dermatol. 2021;7(4):403-410. doi: 10.1016/j.ijwd.2021.02.010. PMID: 34632036; PMCID: PMC8484989. Go to original source... Go to PubMed...
  14. Florence J. Dalgard, Uwe Gieler, Lucia Tomas-Aragones, Lars Lien, Francoise Poot, et al. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries, Journal of Investigative Dermatology. 2015;135(4):984-991,ISSN 0022-202X. Go to original source... Go to PubMed...
  15. Edelstein BA, Drozdick LW, Ciliberti CM. Chapter 1 - Assessment of Depression and Bereavement in Older Adults. Editor(s): Peter A. Lichtenberg. Handbook of Assessment in Clinical Gerontology (Second Edition), Academic Press. 2010:3-43. ISBN 9780123749611. Go to original source...
  16. Dieris-Hirche J, Gieler U, Kupfer JP, Milch WE. Suizidgedanken, Angst und Depression bei erwachsenen Neurodermitikern [Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis]. Hautarzt. 2009;60(8):641-646. German. Go to original source... Go to PubMed...
  17. Dieris-Hirche J, Gieler U, Petrak F, Milch W, et al. Suicidal Ideation in Adult Patients with Atopic Dermatitis: A Ger­man Cross-sectional Study. Acta Derm Venereol. 2017; 97(10):1189-1195. Go to original source... Go to PubMed...
  18. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. Go to original source... Go to PubMed...
  19. https://www.prolekare.cz/tema/systemova-lecba-ad-a-astmatu/detail/co-je-to-skore-easi-a-jak-se-pocita-127063.
  20. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007;157(4):645-648. doi: 10.1111/j.1365-2133.2007.08112.x. Epub 2007 Aug 21. PMID: 17714568. Go to original source... Go to PubMed...
  21. Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011;41:149-155. Go to original source... Go to PubMed...
  22. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850-878. Go to original source... Go to PubMed...
  23. Brodská P. Léčba středně těžkého a těžkého atopického ekzému u dospělých pacientů. Dermatol. praxi. 2019;13(1): 9-12. DOI: 10.36290/der.2019.002. Go to original source...
  24. Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797-1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12. PMID: 33991374; PMCID: PMC8453983. Go to original source... Go to PubMed...
  25. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_cs.pdf.
  26. https://www.biospace.com/article/leo-pharma-s-tralokinumab-news-what-you-need-to-know/.
  27. Olumiant. Prescribing information. Eli Lilly, Indianapolis, IN, 2020.
  28. https://www.sukl.cz/modules/medication/detail.php?code=0238971&tab=available.
  29. Mostafa N, Phan K, Lai B, Smith SD. Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis, Expert Review of Clinical Pharmacology. 2021;14:11, 1435-1444, DOI: 10.1080/17512433.2021.1970529. Go to original source... Go to PubMed...
  30. Thaçi D, Simpson LE, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266-275. doi: 10.1016/j.jdermsci.2019.02.002. Epub 2019 Mar 12. PMID: 31109652. Go to original source... Go to PubMed...
  31. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. PMID: 33000465; PMCID: PMC7986411. Go to original source... Go to PubMed...
  32. https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf.
  33. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol.2020;156(4):411-420. doi:10.1001/jamadermatol.2020.0079 Go to original source... Go to PubMed...
  34. Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Erratum in: Lancet. 2021 Jun 19;397(10292):2336. Erratum in: Lancet. 2021Aug 28;398(10302):746. PMID: 34023009. Go to original source... Go to PubMed...
  35. AbbVie. European commission approves Rinvoq® (Upadacitinib) as first JAK inhibitor in the European Union for the treatment of both adults and adolescents with moderate to severe atopic dermatitis. Accessed August 24, 2021.
  36. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Erratum in: Lancet. 2021;397(10290):2150. PMID: 34023008. Go to original source... Go to PubMed...
  37. Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020;156(8):863-873. doi: 10.1001/jamadermatol.2020.1406. PMID: 32492087; PMCID: PMC7271424. Go to original source... Go to PubMed...
  38. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. PMID: 33761207. Go to original source... Go to PubMed...
  39. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, et al. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary. Immunotherapy. 2022;14(1):5-14. doi: 10.2217/imt-2021-0224. Epub 2021 Nov 15. PMID: 34775830. Go to original source... Go to PubMed...
  40. Kelsey B. Nusbaum, Sarah Fleischer & Alan B. Fleischer Jr. (2021) Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2021.1986204. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.